Marcela V. Maus, Ph.D.

Affiliations: 
University of Pennsylvania, Philadelphia, PA, United States 
Google:
"Marcela Maus"

Parents

Sign in to add mentor
Carl H. June grad student 2003 Penn
 (Biology of human T cell activation.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Maus MV, Alexander S, Bishop MR, et al. (2020) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal For Immunotherapy of Cancer. 8
Weber EW, Maus MV, Mackall CL. (2020) The Emerging Landscape of Immune Cell Therapies. Cell. 181: 46-62
Garfall AL, Stadtmauer EA, Hwang WT, et al. (2019) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Jci Insight. 4
Lee DW, Santomasso BD, Locke FL, et al. (2018) ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation
Boyiadzis MM, Dhodapkar MV, Brentjens RJ, et al. (2018) Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. Journal For Immunotherapy of Cancer. 6: 137
Choi BD, Maus MV, June CH, et al. (2018) ----Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Kloss CC, Lee J, Zhang A, et al. (2018) Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Molecular Therapy : the Journal of the American Society of Gene Therapy
Garfall AL, Stadtmauer EA, Hwang WT, et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Jci Insight. 3
O'Rourke DM, Nasrallah MP, Desai A, et al. (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine. 9
Long M, Beckwith K, Do P, et al. (2017) Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of Clinical Investigation
See more...